Premier Research acquires regulatory firm RPI for undisclosed price

Handshake business deal executives
CRO Premier Research acquired Regulatory Professionals and will merge the regulatory firm into a new division. (Pixabay)

Global CRO Premier Research acquired Regulatory Professionals and will merge the firm into a new division focused on the regulatory process for biotech, pharma and medical device companies.

Premier Research, which is backed by the investment firm Metalmark Capital, didn’t disclose financial terms of the deal, though it announced that RPI founder and chief executive Donna Kato will head the newly created division.

RPI, based in San Francisco, was founded in 1995 and offers regulatory experience across a number of product areas and life cycles from oncology to dermatology, the company said.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“Taking a new drug or medical device from concept to market requires a thoughtful regulatory strategy, expertly prepared documents for agency submission, and submission management in accordance with increasingly stringent requirements,” Ludo Reynders, Premier’s chief executive, said in a statement. “Joining with RPI will expand our ability to help these pioneers realize the potential of their novel therapies and life-changing innovations.”

William Blair & Company advised on the deal for Premier along with law firm Ropes & Gray. RPI was advised Edgemont Capital Partners, Lowenstein Sandler, and KPMG.

New York-based Metalmark Capital took a stake in Premier Research back in 2016, acquiring its position in the CRO from Indigo Capital, a London-based investment firm.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.